RxDoctor Payments Data

Lily Enayati, MD

Internal Medicine · San Mateo, CANPI 1447322847

Payments from drug & device makers

$1,246in general payments, 2019–2025

Across 42 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$344
  • Novo Nordisk$271
  • Pfizer$221
  • Boehringer Ingelheim$93
  • Amgen$84
  • AstraZeneca$56
  • plus $177 from 7 others

What the payments were for

  • Food & beverage$1,246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,246 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$344,778
Medicare patients
392
Services billed
2,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide50$52,814
OzempicSemaglutide45$43,204
EliquisApixaban34$39,751
JanuviaSitagliptin Phosphate18$28,193
JardianceEmpagliflozin17$27,320
RybelsusSemaglutide16$19,549
Atorvastatin Calcium689$8,238
PremarinEstrogens, Conjugated12$6,501
Levothyroxine Sodium376$5,490
BrilintaTicagrelor11$4,590
SynthroidLevothyroxine Sodium44$4,436
Losartan Potassium230$2,903
Wixela InhubFluticasone Propion/Salmeterol13$2,741
Metformin Hcl292$2,615
Amlodipine Besylate284$2,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$271$62,75261 claims
Lilly USA, LLCMounjaro$344$52,81450 claims
PfizerEliquis, Premarin, Paxlovid$221$47,68171 claims
Boehringer IngelheimJardiance$93$27,32017 claims
AstraZenecaBrilinta$56$4,59011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Mateo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →